Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0NMCNN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD48A
|
|||||
| Synonyms |
SGN-CD48A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
|
|
||||||
| Antibody Name |
Anti-SLAMF2 mAb
|
Antibody Info | Antigen Name | |||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
PEGylated β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
1.00-11.00
|
ng/mL
|
Multiple myeloma cells
|
Multiple myeloma
|
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients must have MM requiring systemic treatment (per IMWG) refractory to prior PI, IMiD, and anti-CD38 antibody therapy, with measurable disease and adequate organ function (ECOG 0-1). Key exclusions: Grade 2+ neuropathy, recent malignancies (past 3 years), active CNS disease, uncontrolled infections (HIV/HBV/HCV), prior allogeneic transplant, recent cardiovascular events, or use of P-gp/CYP3A modulators within 14 days.
Click to Show/Hide
|
||||
| Administration Dosage |
Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03379584 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma | ||||
| Primary Endpoint |
Safety outcomes monitor adverse events (AEs) including severity, seriousness, and relatedness through 1 month after the last dose, along with laboratory abnormalities and dose-limiting toxicities (DLTs) within 3 weeks of first treatment.
|
||||
| Other Endpoint |
Efficacy measures include objective response rate (ORR; stringent CR/CR/VGPR/PR), CR rate, duration of response (DOR and CR duration up to ~3 years), PFS, OS, pharmacokinetics (blood concentrations of SGN-CD48A/metabolites), and incidence of antitherapeutic antibodies.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 75% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | EJM cells | CVCL_2030 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 87.50% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | U-266 cells | CVCL_0015 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100% | Positive SLAMF2 expression (SLAMF2+++/++) | ||
| Method Description |
SGN-CD48A was evaluated in vivo for antitumor activity in a diffuse MM cell line xenograft model in mice. SGN-CD48A was administered at a single dose of 0.30 mg/kg.
|
||||
| In Vivo Model | Multiple myeloma CDX model | ||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 1.00-11.00 ng/mL | High CD48 expresion (CD48+++/++; 1260 MSLN molecules/cell) | ||
| Method Description |
Cytotoxic activity of SGN-CD48A was demonstrated in a panel of human MM cell lines in vitro.
|
||||
| In Vitro Model | Multiple myeloma | Multiple myeloma cells | Homo sapiens | ||
References